Associations between amyloid β and white matter hyperintensities: A systematic review

Alzheimer's and Dementia

Volumn 13, Issue 10, 2017, Pages 1154-1167

  Roseborough, Austyn ^a   Ramirez, Joel ^a,b   Black, Sandra E ^a,b,c   Edwards, Jodi D ^a,b  

^a Canada   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Alzheimer's disease; Amyloid; Dementia; Systematic review; White matter disease

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

COCHRANE LIBRARY; DIAGNOSIS RELATED GROUP; EMBASE; HUMAN; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; POTENTIAL DIFFERENCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCINFO; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; WHITE MATTER; WHITE MATTER HYPERINTENSITY; ALZHEIMER DISEASE; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS; WHITE MATTER;

EID: 85016606783     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2017.01.026     Document Type: Review

References (79)

1. Alzheimer's Disease International. World Alzheimer Report 2014: dementia and risk reduction an analysis of protective and modifiable factors. 2014, Alzheimer's Disease International, London.
2. Decarli, C., Murphy, D.G., Tranh, M., Grady, C.L., Haxby, J.V., Gillette, J.A., et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 45 (1995), 2077–2084.
3. Garde, E., Lykke Mortensen, E., Rostrup, E., Paulson, O.B., Decline in intelligence is associated with progression in white matter hyperintensity volume. J Neurol Neurosurg Psychiatry 76 (2005), 1289–1291.
4. Schmidt, R., Ropele, S., Enzinger, C., Petrovic, K., Smith, S., Schmidt, H., et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study. Ann Neurol 58 (2005), 610–616.
5. Debette, S., Markus, H.S., The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 341 (2010), 1–9.
6. Pantoni, L., Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9 (2010), 689–701.
7. Gorelick, P.B., Scuteri, A., Black, S.E., Decarli, C., Greenberg, S.M., Iadecola, C., et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42 (2011), 2672–2713.
8. Jellinger, K.A., The enigma of mixed dementia. Alzheimers Dement 3 (2007), 40–53.
9. Villeneuve, S., Jagust, W.J., Imaging vascular disease and amyloid in the aging brain: implications for treatment. J Prev Alzheimers Dis 2 (2015), 64–70.
10. Wardlaw, J.M., Smith, E.E., Biessels, G.J., Cordonnier, C., Fazekas, F., Frayne, R., et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 12 (2013), 822–838.
11. Andin, U., Gustafson, L., Passant, U., Brun, A., A clinico-pathological study of heart and brain lesions in vascular dementia. Dement Geriatr Cogn Disord 19 (2005), 222–228.
12. Barber, R., Scheltens, P., Gholkar, A., Ballard, C., McKeith, I., Ince, P., et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 67 (1999), 66–72.
13. Bowen, B.C., Barker, W.W., Loewenstein, D.A., Sheldon, J., Duara, R., MR signal abnormalities in memory disorder and dementia. AJNR Am J Neuroradiol 11 (1990), 283–290.
14. Fazekas, F., Chawluk, J.B., Zimmerma, A., June, M., MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149 (1987), 351–356.
15. Braak, H., Braak, E., Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16 (1995), 271–284.
16. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004), 306–319.
17. Grimmer, T., Faust, M., Auer, F., Alexopoulos, P., Forstl, H., Henriksen, G., et al. White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol Aging 33 (2012), 2766–2773.
18. Lee, J.H., Kim, S.H., Kim, G.H., Seo, S.W., Park, H.K., Oh, S.J., et al. Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B. Neurology 77 (2011), 18–25 [Erratum appears in Neurology. 2011 Aug 30;77(9):923].
19. Gordon, B.A., Najmi, S., Hsu, P., Roe, C.M., Morris, J.C., Benzinger, T.L., The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. Neuroimage Clin 8 (2015), 246–252.
20. Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Grp, P., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther 89 (2009), 873–880 (Reprinted from Annals of Internal Medicine).
21. von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gøtzsche, P.C., Vandenbroucke, J.P., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 12 (2014), 1495–1499.
22. Brickman, A.M., Guzman, V.A., Gonzalez-Castellon, M., Razlighi, Q., Gu, Y., Narkhede, A., et al. Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. Neurosci Lett 592 (2015), 54–58.
23. Lopez, O.L., Klunk, W.E., Mathis, C., Coleman, R.L., Price, J., Becker, J.T., et al. Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology 83 (2014), 1804–1811.
24. Provenzano, F.A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B.T., Griffith, E.Y., et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?. JAMA Neurol 70 (2013), 455–461.
25. Sojkova, J., Beason-Held, L., Zhou, Y., An, Y., Kraut, M.A., Ye, W., et al. Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern?. J Nucl Med 49 (2008), 1465–1471.
26. Vemuri, P., Lesnick, T.G., Przybelski, S.A., Knopman, D.S., Preboske, G.M., Kantarci, K., et al. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain 138 (2015), 761–771.
27. Knopman, D.S., Jack, C.R. Jr., Wiste, H.J., Weigand, S.D., Vemuri, P., Lowe, V.J., et al. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol 73 (2013), 472–480.
28. Marchant, N.L., Reed, B.R., Decarli, C.S., Madison, C.M., Weiner, M.W., Chui, H.C., et al. Cerebrovascular disease, beta-amyloid, and cognition in aging. Neurobiol Aging 33 (2012), e25–e36.
29. Wirth, M., Villeneuve, S., Haase, C.M., Madison, C.M., Oh, H., Landau, S.M., et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70 (2013), 1512–1519.
30. Hughes, T.M., Kuller, L.H., Barinas-Mitchell, E.J., Mackey, R.H., McDade, E.M., Klunk, W.E., et al. Pulse wave velocity is associated with beta-amyloid deposition in the brains of very elderly adults. Neurology 81 (2013), 1711–1718.
31. Yates, P.A., Desmond, P.M., Phal, P.M., Steward, C., Szoeke, C., Salvado, O., et al. Incidence of cerebral microbleeds in preclinical Alzheimer disease. Neurology 82 (2014), 1266–1273.
32. Villeneuve, S., Reed, B.R., Wirth, M., Haase, C.M., Madison, C.M., Ayakta, N., et al. Cortical thickness mediates the effect of beta-amyloid on episodic memory. Neurology 82 (2014), 761–767.
33. Gurol, M.E., Viswanathan, A., Gidicsin, C., Hedden, T., Martinez-Ramirez, S., Dumas, A., et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study. Ann Neurol 73 (2013), 529–536.
34. Yoon, C.W., Shin, J.S., Kim, H.J., Cho, H., Noh, Y., Kim, G.H., et al. Cognitive deficits of pure subcortical vascular dementia vs. Alzheimer disease: PiB-PET-based study. Neurology 80 (2013), 569–573.
35. Ye, B.S., Seo, S.W., Kim, G.H., Noh, Y., Cho, H., Yoon, C.W., et al. Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. Alzheimers Dement 11 (2015), 494–503.e3.
36. Kim, Y.J., Kwon, H.K., Lee, J.M., Kim, Y.J., Kim, H.J., Jung, N.Y., et al. White matter microstructural changes in pure Alzheimer's disease and subcortical vascular dementia. Eur J Neurol 22 (2015), 709–716.
37. Kim, H.J., Kim, J., Cho, H., Ye, B.S., Yoon, C.W., Noh, Y., et al. Individual subject classification of mixed dementia from pure subcortical vascular dementia based on subcortical shape analysis. PLoS One 8 (2013), 1–9.
38. Kim, G.H., Lee, J.H., Seo, S.W., Ye, B.S., Cho, H., Kim, H.J., et al. Seoul criteria for PiB(-) subcortical vascular dementia based on clinical and MRI variables. Neurology 82 (2014), 1529–1535.
39. Noh, Y., Seo, S.W., Jeon, S., Lee, J.M., Kim, J.H., Kim, G.H., et al. White matter hyperintensities are associated with amyloid burden in APOE4 non-carriers. J Alzheimers Dis 40 (2014), 877–886.
40. Park, J.H., Seo, S.W., Kim, C., Kim, S.H., Kim, G.H., Kim, S.T., et al. Effects of cerebrovascular disease and amyloid beta burden on cognition in subjects with subcortical vascular cognitive impairment. Neurobiol Aging 35 (2014), 254–260.
41. Park, J.H., Seo, S.W., Kim, C., Kim, G.H., Noh, H.J., Kim, S.T., et al. Pathogenesis of cerebral microbleeds: in vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann Neurol 73 (2013), 584–593.
42. Noh, H.J., Seo, S.W., Jeong, Y., Park, J.E., Kim, G.H., Noh, Y., et al. Blood viscosity in subcortical vascular mild cognitive impairment with versus without cerebral amyloid burden. J Stroke Cerebrovasc Dis 23 (2014), 958–966.
43. Kim, H.J., Kang, S.J., Kim, C., Kim, G.H., Jeon, S., Lee, J.M., et al. The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. Neurobiol Aging 34 (2013), 1913–1920.
44. Kim, H.J., Ye, B.S., Yoon, C.W., Cho, H., Noh, Y., Kim, G.H., et al. Effects of APOE ε4 on brain amyloid, lacunar infarcts, and white matter lesions: a study among patients with subcortical vascular cognitive impairment. Neurobiol Aging 34 (2013), 2482–2487.
45. Marchant, N.L., Reed, B.R., Sanossian, N., Madison, C.M., Kriger, S., Dhada, R., et al. The aging brain and cognition: contribution of vascular injury and Aβ to mild cognitive dysfunction. JAMA Neurol 70 (2013), 488–495.
46. Ortner, M., Kurz, A., Alexopoulos, P., Auer, F., Diehl-Schmid, J., Drzezga, A., et al. Small vessel disease, but neither amyloid load nor metabolic deficit, is dependent on age at onset in Alzheimer's disease. Biol Pyschiatry 77 (2015), 704–710.
47. Zhou, Y., Yu, F., Duong, T.Q., for Alzheimer's Disease Neuroimaging Initiative. White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients. J Magn Reson Imaging 41 (2015), 102–109.
48. Zazulia, A.R., Videen, T.O., Morris, J.C., Powers, W.J., Autoregulation of cerebral blood flow to changes in arterial pressure in mild Alzheimer's disease. J Cereb Blood Flow Metab 30 (2010), 1883–1889.
49. Gurol, E.M., Gidicsin, C., Dumas, A., Hedden, T., Ayres, A., Becker, A., et al. Cerebral amyloid angiopathy independently contributes to ischemic white matter disease: a PET/MRI correlative study. Ann Neurol, 72, 2012, S43.
50. Madsen, K., Hasselbalch, B.J., Frederiksen, K.S., Haahr, M.E., Gade, A., Law, I., et al. Lack of association between prior depressive episodes and cerebral [11C]PiB binding. Neurobiol Aging 33 (2012), 2334–2342.
51. Huang, K.L., Lin, K.J., Ho, M.Y., Chang, Y.J., Chang, C.H., Wey, S.P., et al. Amyloid deposition after cerebral hypoperfusion: evidenced on [18F]AV-45 positron emission tomography. J Neurol Sci 319 (2012), 124–129.
52. Kim, H.J., Ye, B.S., Yoon, C.W., Noh, Y., Kim, G.H., Cho, H., et al. Cortical thickness and hippocampal shape in pure vascular mild cognitive impairment and dementia of subcortical type. Eur J Neurol 21 (2014), 744–751.
53. Wirth, M., Haase, C.M., Villeneuve, S., Vogel, J., Jagust, W.J., Neurobiology of aging neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. Neurobiol Aging 35 (2014), 1873–1882.
54. Villeneuve, S., Reed, B.R., Madison, C.M., Wirth, M., Marchant, N.L., Kriger, S., et al. Vascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions. Neurology 83 (2014), 40–47.
55. Jack, C.R. Jr., Wiste, H.J., Lesnick, T.G., Weigand, S.D., Knopman, D.S., Vemuri, P., et al. Brain beta-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
56. Marnane, M., Al-jawadi, O.O., Pogorzelec, K.J., Wang, B.W., Feldman, H.H., Ging-Yuck, H.R., Periventricular hyperintensities are associated with elevated cerebral amyloid. Neurology 86 (2016), 535–543.
57. Riley, K.P., Snowdon, D.A., Markesbery, W.R., Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study. Ann Neurol 51 (2002), 567–577.
58. Klunk, W.E., Wang, Y., Huang, G.F., Debnath, M.L., Holt, D.P., Mathis, C.A., Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 69 (2001), 1471–1484.
59. Choi, S.R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Benedum, T.E., et al. NIH public access: preclinical properties of 18 F-AV-45: a PET agent for Aβ plaques in the brain. J Nucl Med 50 (2009), 1887–1894.
60. Weller, R.O., Subash, M., Preston, S.D., Mazanti, I., Carare, R.O., Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 18 (2008), 253–266.
61. Tarasoff-Conway, J.M., Carare, R.O., Osorio, R.S., Glodzik, L., Butler, T., Fieremans, E., et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 11 (2015), 457–470.
62. Iturria-Medina, Y., Sotero, R.C., Toussaint, P.J., Evans, A.C., Epidemic spreading model to characterize misfolded proteins propagation in aging and associated neurodegenerative disorders. PLoS Comput Biol, 10, 2014, e1003956.
63. Reed, B.R., Marchant, N.L., Jagust, W.J., DeCarli, C.C., Mack, W., Chui, H.C., Coronary risk correlates with cerebral amyloid deposition. Neurobiol Aging 33 (2012), 1979–1987.
64. Kuller, L., Hughes, T., Barinas-Mitchell, E., Mackey, R., McDade, E., Klunk, W.E., et al. Arterial stiffness is associated with amyloid deposition in the brain independent of blood pressure. Alzheimers Dement 1 (2013), P543–P544.
65. Coon, K.D., Myers, A.J., Craig, D.W., Webster, J.A., Pearson, J.V., Lince, D.H., et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68 (2007), 613–618.
66. Benzinger, T.L., Blazey, T., Jack, C.R., Koeppe, R.A., Su, Y., Xiong, C., et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A 110 (2013), E4502–E4509.
67. Lee, S., Viqar, F., Zimmerman, M.E., Narkhede, A., Tosto, G., Benzinger, T.L.S., et al. White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network. Ann Neurol 79 (2016), 929–939.
68. Skrobot, O.A., McKnight, A.J., Passmore, P.A., Seripa, D., Mecocci, P., Panza, F., et al. A validation study of vascular cognitive impairment genetics meta-analysis findings in an independent collaborative cohort. J Alzheimers Dis 53 (2016), 981–989.
69. Chang, K.J., Hong, C.H., Lee, K.S., Roh, H.W., Choi, S.H., Kim, S.Y., et al. Differential effects of white matter hyperintensity on geriatric depressive symptoms according to APOE- ε 4 status. J Affect Disord 188 (2015), 28–34.
70. Brickman, A.M., Schupf, N., Manly, J.J., Stern, Y., APOE ε4 and risk for Alzheimer's disease: do regionally distributed white matter hyperintensities play a role?. Alzhiemers Dement 10 (2014), 619–629.
71. Habes, M., Erus, G., Toledo, J.B., Zhang, T., Bryan, N., Launer, L.J., et al. White matter hyperintensities and imaging patterns of brain ageing in the general population. Brain, 2016, 1164–1179.
72. Ryan, N.S., Biessels, G., Kim, L., Nicholas, J.M., Barber, P.A., Walsh, P., et al. Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiol Aging 36 (2015), 3140–3151.
73. Lyall, D.M., Maniega, S.M., Harris, S.E., Bastin, M.E., Murray, C., Lutz, M.W., et al. APOE/TOMM40 genetic loci, white matter hyperintensities, and cerebral microbleeds. Int J Stroke 10 (2015), 1297–1300.
74. Weller, R.O., Hawkes, C.A., Kalaria, R.N., Werring, D.J., Carare, R.O., White matter changes in dementia: role of impaired drainage of interstitial fluid. Brain Pathol 25 (2015), 63–78.
75. Gesierich, B., Opherk, C., Rosand, J., Gonik, M., Malik, R., Jouvent, E., et al. APOE ε2 is associated with white matter hyperintensity volume in CADASIL. J Cereb Blood Flow Metab 36 (2016), 199–203.
76. Sachdev, P., Kalaria, R., O'Brien, J., Skoog, I., Alladi, S., Black, S., et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord 28 (2014), 206–218.
77. Jack, C.R. Jr., Knopman, D.S., Jagust, W.J., Shaw, L.M., Aisen, P.S., Weiner, M.W., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet 9 (2010), 1–20.
78. Rowe, C.C., Ellis, K.A., Rimajova, M., Bourgeat, P., Pike, K.E., Jones, G., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31 (2010), 1275–1283.
79. Pike, K.E., Savage, G., Villemagne, V.L., Ng, S., Moss, S.A., Maruff, P., et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130 (2007), 2837–2844.